🌿 Roundup (Weed Killer) Non-Hodgkin Lymphoma Class Settlement

Plaintiffs allege that exposure to Roundup and other glyphosate-based weed killers caused non-Hodgkin lymphoma.

People in the U.S. exposed to Roundup or other glyphosate-based weed killers before February 17, 2026 who have been, or are later, diagnosed with non-Hodgkin lymphoma (diagnoses within 16 years of final approval remain eligible).

Individual awards estimated in the range of $6,000-$165,000+ depending on exposure/medical tier, drawn from a fund of up to $7.25 billion paid out over 17-21 years.

None

The proposed deal, submitted for preliminary court approval on February 17, 2026 and approved on March 4, 2026, would create a fund of roughly $7.25 billion, with individual payouts estimated to range from about $6,000 up to $165,000 or more depending on the specifics of each case. People who are diagnosed with non-Hodgkin lymphoma after the settlement takes effect can still file later, since the deal allows claims within six years of diagnosis or before the fund's 16th annual payment date, whichever comes first. The fairness hearing where a judge will decide whether to grant final approval was originally set for July 9, 2026 but has since been pushed back to August 19, 2026.